| Anecdotal reports suggest that the psychedelic substance psilocybine helps to relieve symptoms of obsessive-compulsive disorder during and after the acute psychedelic experience. Psilocybine is a potent 5-HT-2A antagonist, which resembles the pharmacological mechanism for antiobsessional drug response. The purpose of this study is to: 1) Establish safety and tolerability of psilocybine in human subjects; 2) Collect preliminary data regarding efficacy of psilocybine treatment in OCD; 3) Explore the dose-response relationship; and 4) Explore the relationship between degree of psychedelic response and antiobsessional effects. Early review of data collected thus far suggests that psilocybine may be safe and well tolerated in subjects with treatment-refractory OCD and may offer at least temporary relief of OCD symptoms. Subjective experiences will be discussed in the context of the subjects psychological, spiritual, and transcendental experiences. |